(24/7 MARKET NEWS) – First Wave BioPharma, Inc. (NASDAQ: FWBI) stated, this morning, that it entered into an agreement with Rho, a full-service contract research organization, for its planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase.
First Wave BioPharma is trading at $1.1811, up $0.0511 (+4.52%), on over 7 million shares.
It’s traded as high as $1.58 in this morning’s premarket and its 52-week range is $1.06 to $92.70, with the next key inflection points at $1.58 and $2.70.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
